A NEW GENERATION OF IMMUNO-ONCOLOGY
Eradicate cancer with next-generation immunotherapies
Next-generation immune-activating medicines against solid tumors, designed with our lab-in-the-loop AI platform.
Next-generation immune-activating medicines against solid tumors, designed with our lab-in-the-loop AI platform.
Human T-cells use T-cell receptors (TCRs) to identify highly specific signs of disease that are present on sick cells and absent on healthy cells.
This natural phenomenon can be harnessed for the development of TCR-based medicines to eradicate solid tumors. However, safe, high-affinity TCRs against cancer targets are rare and hard to identify using traditional wet-lab methods.
Exogene combines generative AI with high-throughput TCR screening in the lab to design effective, safe and developable TCR-based medicines.
Our generative AI platform mines the TCR sequence space to discover novel, high-affinity and high-specificity candidates against targets shared across patients and tumor types.
A key data-generation advantage is our full-length TCR yeast display platform, which enables high-throughput experimental validation of AI predictions (lab-in-the-loop). The data feeds back into the models, creating an active learning loop that continuously improves prediction and design.
Our multidisciplinary team brings together computational biology, machine learning, protein science and therapeutic development.
Sebastian was the scientific mastermind behind the T cell engager programmes at Immatics (NASDAQ: IMTX). He spearheaded IMA401 and IMA402 from discovery all the way to first-in-human clinical trials, and unlocked the $150M upfront deal with BMS. Sebastian brings key scientific and commercial experience to help us develop and advance our assets towards the clinic.
Muhammad holds a PhD in Mathematical Biology and Biophysical Chemistry from the University of Warwick. Over the last decade, he has worked on a broad range of protein engineering and structural biology projects at the interface of Physics, Chemistry and Biology. Prior to joining Exogene, he had been working on developing novel methods for the study and diagnostics of the SARS-CoV-2 virus.
Jan-Gert is a protein biochemist with a PhD in Biology from the University of York. He previously worked at Memorial Sloan Kettering Cancer Center (MSKCC) developing in vitro assays to study how the DNA replication machinery deals with obstacles such as DNA damage and protein roadblocks to maintain genome integrity.
Alex is an experienced machine learning expert specialising in AI for biomedical research. At Ardigen, he served as a SCRUM master and developed models to predict peptide-HLA and TCR-pHLA binding. During his PhD at the Warsaw University of Technology, he focused on in-silico modelling of antigen recognition using machine learning.
Ryan is an experienced machine learning scientist with a PhD in Chemistry from Cornell University. He joined Exogene from the machine learning group at Bayer and his recent work there was published at ICML. He previously worked at Intel, and in his spare time he participates in machine learning competitions.
Foram is a cell biologist and immunologist with over five years of experience in oncology and immunotherapy. She earned her PhD from the University of Plymouth and has since contributed to cutting-edge research at Scancell, where she played a pivotal role in advancing bispecific T-cell engager programs through both in vitro and in vivo preclinical development.
Jose Enrique holds a PhD in Pharmacology from the University of Cambridge. His doctoral research focused on the selection and characterisation of functional antibodies or nanobodies targeting challenging neuronal ion channels. Through his prior work, he has acquired significant experience in molecular biology, protein engineering, structural biology, and yeast display technology.
Anthony is a molecular cell biologist with a PhD in Cellular Microbiology from the University of Cambridge. Whilst working in Academia he specialised in Host-Pathogen Interactions with a decade of research dedicated to the molecular mechanisms of bacterial entry. He recently transitioned into industry using his skills in cell engineering and assay development to characterise novel T-cell engagers.
Livio is the co-founder of Vaxess Technologies, where he has pioneered a novel vaccine patch, raised over $80 million in funding, and collaborated with AstraZeneca on mRNA vaccine technologies. Before Vaxess, he worked at the United Nations, implementing silk production programs in Asia. Livio was named in the 2014 Forbes 30 under 30 list and holds a Masters in Public Policy from Harvard Kennedy School.
© 2026 Exogene. All rights reserved.
Wood Centre for Innovation, Stansfeld Park, Quarry Road, Headington, Oxford, OX3 8SB
Company registration no. 12293407